Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANTX | An2 Therapeutics | $5.67 | $2.82 | 98.95% | 54.4M | $78M | $1.00$6.91 |
| DTCK | Davis Commodities | $2.70 | $1.27 | 88.46% | 29.2M | $39M | $1.32$137.80 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $2.04 | $0.92 | 81.70% | 159.1M | - | $0.88$55.77 |
| CAMP | Camp4 Therapeutics | $6.90 | $2.70 | 64.29% | 4.8M | $218M | $1.31$7.75 |
| RLMD | Relmada Therapeutics | $7.04 | $2.59 | 58.16% | 38.9M | $326M | $0.24$7.14 |
| TURB | Turbo Energy | $5.51 | $1.73 | 45.77% | 21.8M | $42M | $0.57$20.45 |
| XENE | Xenon Pharmaceuticals | $60.90 | $18.96 | 45.21% | 555.9K | $3.5B | $26.74$62.74 |
| HIMS | Hims & Hers Health | $22.23 | $6.49 | 41.23% | 5.7M | $3.6B | $13.74$70.43 |
| ATRA | Atara Biotherapeutics | $7.00 | $1.83 | 35.40% | 64.7K | $37M | $3.92$19.15 |
| NERV | Minerva Neurosciences | $8.04 | $2.03 | 33.69% | 427.4K | $260M | $1.15$12.46 |
| PLYX | Polaryx Therapeutics | $3.60 | $0.86 | 31.39% | 658.7K | $130M | $2.20$48.91 |
| EPSM | Epsium Enterprise | $2.20 | $0.46 | 26.44% | 69.1K | $23M | $1.04$155.00 |
| RNAC | Cartesian Therapeutics | $8.62 | $1.77 | 25.84% | 2.6M | $178M | $5.98$18.80 |
| PIII | P3 Health Partners | $2.80 | $0.57 | 25.56% | 174.7K | $7.3M | $1.52$11.30 |
| DDD | 3D Systems | $2.45 | $0.49 | 25.00% | 231.3K | $252M | $1.32$3.80 |
| QURE | uniQure | $17.35 | $3.08 | 21.58% | 498.1K | $879M | $7.76$71.50 |
| LSTA | Lisata Therapeutics | $5.03 | $0.85 | 20.21% | 403.1K | $37M | $1.81$5.06 |
| CCCC | C4 Therapeutics | $3.64 | $0.60 | 19.74% | 242.2K | $297M | $1.09$3.82 |
| PURR | Hyperliquid Strategies | $5.16 | $0.83 | 19.17% | 6.9M | $537M | $3.01$5.78 |
| DYN | Dyne Therapeutics | $17.65 | $2.79 | 18.77% | 120K | $2.5B | $6.36$25.00 |
| DNTH | Dianthus Therapeutics | $77.19 | $11.99 | 18.39% | 132.9K | $2.8B | $13.37$84.78 |
| KC | Kingsoft Cloud | $14.19 | $2.20 | 18.35% | 120.3K | $3.5B | $10.29$19.57 |
| CRBP | Corbus Pharmaceuticals | $9.43 | $1.42 | 17.73% | 18.7K | $141M | $4.64$20.56 |
| CRVO | CervoMed | $4.83 | $0.72 | 17.40% | 211.1K | $38M | $1.92$16.94 |
| RGNX | Regenxbio | $10.10 | $1.45 | 16.76% | 94.7K | $438M | $5.04$16.19 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $30.38 | $4.24 | 16.21% | 36.1K | - | $10.89$50.61 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $4.03 | $0.56 | 16.14% | 30.2M | - | $0.95$20.92 |
| BIRD | Allbirds | $2.87 | $0.39 | 15.73% | 733 | $20M | $2.42$12.85 |
| FOFO | Hang Feng Technology Innovation | $3.90 | $0.46 | 13.37% | 32.1K | - | $2.86$68.00 |
Related Articles
Featured Article
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Geoffrey Seiler|Mar 9, 2026
Hims & Hers stock traded more than 40% higher after the deal was announced.
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
